Cohort1: AZD9150_dose level1
|
Administration route |
intravenous infusion |
Dosage |
AZD9150, 1mg/kg |
Age |
Adult, Older_Adult |
Adverse reactions |
no AZD9150 related Adverse reactions |
|
Cohort2: AZD9150_dose level2
|
Administration route |
intravenous infusion |
Dosage |
AZD9150, 1.5mg/kg |
Age |
Adult, Older_Adult |
Adverse reactions |
no AZD9150 related Adverse reactions |
|
Cohort3: AZD9150_dose level3
|
Administration route |
intravenous infusion |
Dosage |
AZD9150, 2mg/kg |
Age |
Adult, Older_Adult |
Adverse reactions |
2/7(Gastrointestinal disorders; Infections and infestations) |
|
Cohort4: AZD9150_dose level4
|
Administration route |
intravenous infusion |
Dosage |
AZD9150, 2.5mg/kg |
Age |
Adult, Older_Adult |
Adverse reactions |
2/5(Gastrointestinal disorders; Hepatobiliary disorders) |
|
Cohort5: AZD9150_dose level5
|
Administration route |
intravenous infusion |
Dosage |
AZD9150, 3mg/kg |
Age |
Adult, Older_Adult |
Adverse reactions |
4/15(Blood and lymphatic system disorders; Gastrointestinal disorders; Infections and infestations) |
|